Latest Acquisitions News

Victor Group Holdings has sharply reduced its FY25 loss to $275,449 from $3.53 million the prior year, while expanding its fintech presence through strategic stakes in LIT Technology and iRich Finance.

Gathid Ltd reported a 142% surge in revenue for FY25 driven by its expanding software business, despite a continuing operations loss and ongoing dispute over the RightCrowd sale proceeds.

Australian Agricultural Projects Limited reported a strong 18% revenue increase and a 56% jump in net profit for FY2025, while preparing to directly manage a key orchard segment after lease changes.

Infinity Mining Limited’s 2025 AGM highlighted significant portfolio reshaping, including asset sales and acquisitions, alongside promising exploration results at the Cangai Copper Project.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.

Waterco Limited reported a 4% increase in FY25 sales revenue to $249.4 million, driven by regional growth and integration benefits from the Davey acquisition. Despite revenue gains, earnings declined due to cost pressures and restructuring, with statutory NPAT down 31%.

Waterco Limited reported a modest 4% revenue increase for FY25 but saw net profit fall sharply by 31%, weighed down by restructuring and foreign exchange losses. The company maintains its dividend and eyes growth through innovation and regional expansion.

SOCO Corporation Ltd reported a 3.6% revenue increase to $21.29 million for FY25, reversing prior losses with a modest net profit after tax. Operational improvements and strategic hires underpin the company’s renewed momentum.

Dexus has announced its 18.0 cents per security distribution for the first half of 2025, alongside robust full-year results that highlight a resilient portfolio and disciplined capital management. The company signals confidence with a steady outlook despite ongoing economic uncertainty.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Resonance Health Limited reported a 29% revenue increase to $11.07 million for FY25 but posted a net loss of $1.73 million, reflecting strategic investments and expansion in clinical trial services.